Senior FDA leadership has publicly acknowledged multiple years of organizational disruption within the agency, with Rick Pazdur citing the extent of internal challenges during remarks at ASCO 2026. The admission underscores the severity of structural issues facing the nation’s primary pharmaceutical regulator. Pazdur, directing the Oncology Center of Excellence for over 30 years, emphasized that the current period of upheaval presents an opportunity rather than merely an obstacle to overcome. The FDA’s acknowledgment of prolonged internal difficulties coincides with mounting pressure from international regulatory agencies, particularly China’s emerging regulatory frameworks, which have begun competing for accelerated drug approvals and breakthrough designations. Industry observers suggest these internal and external pressures may catalyze significant changes to drug approval timelines, oversight mechanisms, and organizational protocols that have governed FDA operations for decades.
Was this article helpful?
